Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Valneva and Pfizer Enter Into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today announced […]
Novartis Receives GB Licence for Scemblix®▼ (Asciminib), the First STAMP Inhibitor for Patients With Chronic Myeloid Leukaemia
Novartis UK has announced that Scemblix® (asciminib) has been granted Marketing Authorisation in Great Britain by […]
Computer Tool Can Track Stroke Rehabilitation to Boost Recovery
A sensor-equipped computer program can accurately identify and count arm movements in people undergoing stroke […]
Nonagen Bioscience Announces CE Mark for Oncuria® Bladder Cancer Diagnostic
Nonagen Bioscience, a cancer diagnostics company, today announced CE marking for its Oncuria® immunoassay for […]
Roche Launches Human Papillomavirus (HPV) Self-sampling Solution, Expanding Cervical Cancer Screening Options
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of a human papillomavirus (HPV) […]
New AI Tool Is Better at Spotting Heart Failure Than Current Tests
A new artificial intelligence (AI) tool can help diagnose acute heart failure more accurately than […]
Center for Breakthrough Medicines Accelerates Plans to Build the Largest Cell Therapy Manufacturing Operation in the World
The Center for Breakthrough Medicines (CBM) in partnership with the Discovery Labs announced today the […]
High Street Pharmacies Spot Cancers In New NHS Early Diagnosis Drive
Staff in high street pharmacies will be funded to spot signs of cancer as part […]
EUROIMMUN Launches Two Assays for the Quantification of SARS-CoV-2 Antibodies
EUROIMMUN, a PerkinElmer company, today announced the launch of two CE marked assays – the […]
Spirea Raises £2.4M ($3M) to Develop Antibody Drug Conjugates in Cancer
Spirea Limited, a Cambridge company created to advance a new generation of antibody drug conjugate […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more